Department of Toxicology of School of Public Health and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
J Zhejiang Univ Sci B. 2021 Oct 15;22(10):876-884. doi: 10.1631/jzus.B2100151.
Since the outbreak of coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) discovered in December 2019, the disease has emerged as a global pandemic (Shi et al., 2020; World Health Organization, 2020). Several studies have shown a higher incidence of COVID-19, as well as related poor outcomes in patients with malignancies as compared with those without them (Liang et al., 2020; Tian et al., 2020). The impact of cancer on COVID-19 may be attri‑buted to the use of antitumor treatments that may disturb the host response to SARS-CoV-2 infection (Wang et al., 2020), while the current studies on this topic have drawn controversial conclusions. Some implied that anticancer treatments might elevate the risk of death (García-Suárez et al., 2020; Liu et al., 2020). On the contrary, others pointed out that this association is not significant (Brar et al., 2020; Lee et al., 2020a). Although previous systematic reviews have investigated this important issue (Wang and Huang, 2020), the heterogeneity of findings is obvious and the general conclusion has remained unclear. Considering this ambiguity, it is difficult for clinicians to make therapeutic decisions when facing patients with both cancer and COVID-19; therefore, a high-quality and accurate evaluation of the impact of anticancer treatments on COVID-19 patients is necessary. Accordingly, we conducted a pooled analysis with the original data of each patient for the first time to provide a comprehensive perspective into the association between anticancer regimens and the outcomes of cancer patients with COVID-19.
自 2019 年 12 月发现的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）爆发以来，该疾病已成为全球大流行（Shi 等人，2020 年；世界卫生组织，2020 年）。几项研究表明，与没有恶性肿瘤的患者相比，COVID-19 的发病率更高，相关不良结局也更多（Liang 等人，2020 年；Tian 等人，2020 年）。癌症对 COVID-19 的影响可能归因于抗肿瘤治疗的使用，这些治疗可能会干扰宿主对 SARS-CoV-2 感染的反应（Wang 等人，2020 年），而目前对此主题的研究得出了有争议的结论。一些研究表明，抗癌治疗可能会增加死亡风险（García-Suárez 等人，2020 年；Liu 等人，2020 年）。相反，其他人则指出这种关联并不明显（Brar 等人，2020 年；Lee 等人，2020a 年）。尽管之前的系统评价已经研究了这个重要问题（Wang 和 Huang，2020 年），但研究结果的异质性非常明显，总体结论仍不清楚。考虑到这种模糊性，当临床医生面对同时患有癌症和 COVID-19 的患者时，很难做出治疗决策；因此，需要对抗癌治疗对 COVID-19 患者的影响进行高质量和准确的评估。因此，我们首次使用每个患者的原始数据进行了汇总分析，为癌症合并 COVID-19 患者的抗癌方案与结局之间的相关性提供了全面的视角。
